Novo Nordisk A/s

This study tests a new medicine, CagriSema, to help people with type 2 diabetes lower their blood sugar. About 400 adults aged 18-64 with diabetes will receive one of two versions of the drug using different injector devices. The study lasts about 38 weeks and compares how well e…

This study tests a new weekly injection, NNC0487-0111, against the approved drug semaglutide in 1000 adults with overweight or obesity and type 2 diabetes. Participants will receive two weekly shots (one active, one placebo) for about a year to see which medicine works better for…

This study tests a new medicine called NNC0662-0419 in 230 adults with obesity (BMI 30 or higher). Researchers want to see if different ways of increasing the dose over time can reduce stomach side effects while still helping people lose at least 25% of their body weight. The stu…

This study looks at the safety and effectiveness of Rybelsus, a pill for type 2 diabetes, in everyday medical practice in Korea. About 600 adults will take the medicine as their doctor prescribes, and researchers will track side effects and blood sugar control for 26 weeks. The g…

This study tests a new medicine called NNC0487-0111 in about 5,600 people who have both heart failure and obesity. Participants receive either the drug or a placebo as a weekly injection. The goal is to see if the drug reduces the risk of death or hospitalization due to heart fai…

This study tests a new medicine, CagriSema, to help people with overweight or obesity lose weight. About 1,400 adults will receive either CagriSema or a placebo using one of two injection devices. The study lasts about one year and measures weight change and side effects.

This early-stage study tests two versions of the experimental medicine cagrilintide in 234 adults with overweight or obesity. Participants receive either version D or version B by chance, and researchers compare how the drug behaves in the body over about 6 months. The goal is to…

This study tests a medicine called CagriSema (a mix of two drugs) in 80 children and teens with type 2 diabetes. The goal is to see if it lowers blood sugar and body weight better than a placebo. The study lasts about 15 months, with everyone getting CagriSema in the second part.

This study tests whether a new medicine called cagrilintide causes fewer stomach side effects than a placebo in people with obesity who had to stop taking other weight-loss drugs (GLP-1s) because of stomach issues. About 114 adults will be randomly assigned to receive either cagr…

This early-stage study tests two different versions of the drug cagrilintide in 50 adults who are overweight or have obesity. Participants will receive injections of either version B or D for about 14 weeks to compare how the drug behaves in the body. The goal is to understand wh…

This early-stage study tests whether a new drug called NNC0113-5840 is safe for people with overweight or obesity. About 48 adults aged 18-55 with a BMI between 25 and 35 will receive either the drug or a placebo. The main goal is to check for side effects and how the drug moves …

This early-stage study is testing a new medicine for overweight and obesity. The main goal is to see how the drug behaves in people with different levels of liver function, from normal to severely reduced. About 35 adults aged 18-80 will take a single dose, and researchers will m…

This study watches 100 adults with X-linked hypophosphatemia (XLH) who are already taking the medicine burosumab. Researchers want to see how phosphate levels in the blood change over time and how they relate to bone health and overall well-being. The goal is to better understand…